New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
You may also be interested in...
AbbVie's investigational monoclonal antibody therapy risankizumab has triumphed against its competitors in three Phase III trials in psoriasis, but will it be too late to the party to enjoy the full commercial benefits?
Q3 revenue grew 10% to $3.29bn, but came in below consensus, mostly due to Otezla. The blockbuster drug's new reality and recent GED-0301 failure in Crohn's disease contributed to Celgene's decision to lower guidance for both 2017 and 2020.
Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.